首页> 外文OA文献 >Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.\ud \ud \ud doi: 10.1186/1756-9966-32-48.\ud PMID: 23902592\ud Codice scopus: 2-s2.0-84880911745\ud CODICE ISI: WOS:000322974300002
【2h】

Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.\ud \ud \ud doi: 10.1186/1756-9966-32-48.\ud PMID: 23902592\ud Codice scopus: 2-s2.0-84880911745\ud CODICE ISI: WOS:000322974300002

机译:癌症干细胞在卵巢癌的生物学和治疗中的新兴作用:创新方法的基本知识和治疗可能性。\ ud \ ud \ ud doi:10.1186 / 1756-9966-32-48。\ ud PMID:23902592 \ ud Codice scopus:2-s2.0-84880911745 \ ud 编码ISI:WOS:000322974300002

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In 2013 there will be an estimated 22,240 new diagnoses and 14,030 deaths from ovarian cancer in the United\udStates. Despite the improved surgical approach and the novel active drugs that are available today in clinical\udpractice, about 80% of women presenting with late-stage disease have a 5-year survival rate of only 30%. In the last\udyears a growing scientific knowledge about the molecular pathways involved in ovarian carcinogenesis has led to\udthe discovery and evaluation of several novel molecular targeted agents, with the aim to test alternative models of\udtreatment in order to overcome the clinical problem of resistance. Cancer stem cells tend to be more resistant to\udchemotherapeutic agents and radiation than more differentiated cellular subtypes from the same tissue. In this\udcontext the study of ovarian cancer stem cells is taking on an increasingly important strategic role, mostly for the\udpotential therapeutic application in the next future. In our review, we focused our attention on the molecular\udcharacteristics of epithelial ovarian cancer stem cells, in particular on possible targets to hit with targeted therapies.
机译:2013年,美国预计将有22,240例新诊断出卵巢癌,140,030例死亡。尽管改进了手术方法并在临床\实践中使用了当今可用的新型活性药物,但约有80%的晚期疾病女性的5年生存率仅为30%。在过去的\ u年中,关于卵巢癌发生的分子途径的科学知识不断发展,导致\发现和评估了几种新型的分子靶向药物,目的是测试替代治疗方法,从而克服卵巢癌的临床问题。抵抗性。癌症干细胞比起来自同一组织的分化程度更高的细胞亚型,更倾向于抗化学治疗剂和放射线。在此背景下,卵巢癌干细胞的研究正发挥着越来越重要的战略作用,主要是在未来的潜在治疗应用中。在我们的综述中,我们将注意力集中在上皮性卵巢癌干细胞的分子\特征上,特别是在靶向疗法可能击中的靶点上。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号